The family in the waiting room is an unscreened population.
A cancer clinic already has the hardest conversation done. The relatives who come with a patient are motivated, under-screened, and usually leave with nothing.
Buy ten or more of any SKU and we match it, free, until your next order.
Shown on the Cancer Screening (CGX) panel. Every panel in the catalogue works the same way.
Sell to the family, carefully.
This is the vertical with the most upside and the least room for sloppy claims. Everything below is written to be defensible in front of an oncologist.
Inherited risk does not change. There is no re-test and no subscription — and we will not invent one.
Most relatives accompanying an adult patient sit inside it.
Your opening order, yours once bought.
Germline screening is risk information. It does not detect cancer, it does not stage or grade anything, and a negative result does not mean a person will not develop the disease. Stool DNA screens asymptomatic average-risk adults for colorectal cancer and a positive result requires diagnostic colonoscopy. Neither panel belongs anywhere near a treatment decision for an affected patient, and we do not market them that way.
Start with one. Stack the second.
We recommend a lead panel from your patient mix rather than from our margin. These are the two that fit this room.
Germline risk is the question a patient’s family is already asking out loud. A buccal swab answers it once, and the result stays useful for the rest of that person’s life. It is risk information, not a diagnosis, and framing it that way is what makes it defensible in an oncology setting.
It is not a cancer detection test and does not indicate whether a patient has cancer now. It does not replace age-appropriate screening.
Colorectal screening non-adherence is overwhelmingly about the colonoscopy, not the risk. A take-home stool DNA box handed to an age-eligible relative removes the appointment from the decision.
Not for a patient with visible rectal bleeding — that is a referral, not a screen. A positive result requires diagnostic colonoscopy.
Every panel ships on the same terms. Adding one adds a revenue line without adding capital, space or chair time. The full catalogue is here.
You buy it. You price it. You keep the difference.
Populate the table with your own volume — these are our assumptions, not your numbers.
| Germline panels / month | You keep each | Monthly | Annual |
|---|---|---|---|
| 5 | $155 | $775 | $9,300 |
| 12 | $155 | $1,860 | $22,320 |
| 25 | $155 | $3,875 | $46,500 |
At the CGX margin. The stool panel stacks at $12 a box with no chair time — thin, but it costs nothing to hand over and it reaches the relative who will not book the colonoscopy.
Baseline. Treat. Prove it moved.
The panel is what makes everything else you sell repeatable, and it creates a second high-value visit per cycle.
Baseline
A panel establishes status before anything is prescribed.
Visit oneIntervention
Your protocol as today, plus whatever the panel indicated. That decision is yours, not ours.
Your protocolRe-test when indicated
A clinically indicated re-test shows what moved — and gives the patient a reason to come back and see it.
Visit twoShow the patient what it is
Two clips per panel, sized for a waiting-room screen or a social post. Download them from the poster page along with the print files.
What the Cancer Screening (CGX) panel measures and how the sample is collected.
What the Cancer Detection Stool panel measures and how the sample is collected.
A poster for the waiting room.
Typeset, not AI-generated — so the text is correct and the claims match the standards page. A4 and US Letter for print, plus a square crop for social.
Your practice name can be added to the footer of any poster — send it with your application and we will supply a personalised set.
What you will ask first
Including the ones where the honest answer costs us the sale.
Does this interfere with our somatic testing?
No. Germline and somatic testing answer different questions and this does not touch your treatment pathway. If a patient needs germline testing as part of their own care, that is a clinical order through your existing pathway, not a cash-pay panel.
Do you provide genetic counselling?
No, and that is a real gap you should weigh. A germline result with clinical implications needs a counsellor, and we do not supply one. If your centre has no counselling pathway, this panel is harder to justify than the economics suggest.
Can we market this to patients directly?
Not as a cancer test, and not as anything that implies detection. We supply material that describes it as inherited-risk information, and we will not approve copy that goes further.
What about a patient who is already affected?
Then this is not the right product. An affected patient’s germline testing is part of their care and belongs in your clinical pathway with counselling attached. This is for the unaffected, under-screened family around them.
What arrives
- Your opening order — buy ten or more and we match it
- One virtual training session for your team
- Provider portal access for results
- The CLIA certificate number and named assay methods
- Print-ready posters and the waiting-room video files
Panels are laboratory-developed tests performed by a CLIA-certified laboratory. They are not FDA-cleared for the indications described and do not diagnose, stage or grade disease. Economics shown are illustrative and not a guarantee of results.